Arcus Biosciences, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDArcus Biosciences, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 90), indicating clear outperformance against the broad market. Earnings growth of 11% provides fundamental context to the price action. Investors should exercise caution due to high volatility (64% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $24.51 | +6.07% | ABOVE |
| 50 SMA | $23.02 | +12.96% | ABOVE |
| 100 SMA | $22.39 | +16.13% | ABOVE |
| 150 SMA | $21.50 | +20.92% | ABOVE |
| 200 SMA | $18.82 | +38.13% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RCUS in an uptrend right now?
RCUS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RCUS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RCUS overbought or oversold?
RCUS's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is RCUS outperforming the market?
RCUS has a Relative Strength (RS) Rating of 90 out of 99. Yes, RCUS is a market leader, outperforming 90% of all stocks over the past 12 months.
Where is RCUS in its 52-week range?
RCUS is trading at $26.00, which is 91% of its 52-week high ($28.72) and 87% above its 52-week low ($7.06).
How volatile is RCUS?
RCUS has a Beta of 1.95 and 52-week volatility of 64%. It's more volatile than the S&P 500 - expect bigger swings.